Research
Adherence
GLP-1 agonists are likely unaffordable for universal healthcare systems due to high prevalence of OSA and high drug costs, potentially exacerbating healthcare inequities.
Be aware that GLP-1 agonists are expensive and may not be covered by public health insurance for OSA, creating a barrier to access for lower-income patients.
ModerateRefutesMEDIUM confidence
The high cost of the medications combined with the high prevalence of OSA means that there is no way that universal healthcare funding schemes can afford these medications... This will no doubt exacerbate inequities in healthcare access and outcome between those from lower versus higher socioeconomic populations.
Why this rating
Based on the authors' estimation of prevalence and cost, not a direct economic study.
Source
The potential impact of <scp>GLP</scp>‐1 agonists on obstructive sleep apnoea
Garun S. Hamilton et al. · Respirology · 2023
DOI 10.1111/resp.14545
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 agonists reduce cardiovascular risk and all-cause mortality in diabetic populations, offering a secondary benefit for OSA patients who have high cardiometabolic risk.Strong
- GLP-1 agonists (specifically Semaglutide and Liraglutide) induce significant weight loss (≥15%) which improves Obstructive Sleep Apnoea (OSA) severity, measured by Apnoea-Hypopnoea Index (AHI), particularly in patients who cannot tolerate CPAP.Good
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →